CSPG4 and glioblastoma: Furthermore, originally named as melanoma-associated chondroitin sulfate proteoglycan upon its cloning [63], NG2/CSPG4 has since been widely implicated in a wide variety of human cancers both as a diagnostic marker and a therapeutic target, including for glioblastoma and melanoma [64, 65].